Compare · BSX vs VJET
BSX vs VJET
Side-by-side comparison of Boston Scientific Corporation (BSX) and Flyte Aviation Inc. (VJET): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and VJET operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.25B, about 44422.0x VJET ($1.4M).
- Over the past year, BSX is down 55.0% and VJET is down 97.6% - BSX leads by 42.6 points.
- BSX has been more active in the news (13 items in the past 4 weeks vs 7 for VJET).
- BSX has more recent analyst coverage (25 ratings vs 0 for VJET).
- Company
- Boston Scientific Corporation
- Flyte Aviation Inc.
- Price
- -
- -
- Market cap
- $63.25B
- $1.4M
- 1M return
- -4.28%
- -46.97%
- 1Y return
- -54.98%
- -97.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 13
- 7
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Flyte Aviation Inc.
Flyte Aviation, Inc. (NYSE American: VJET) is a technology-enabled private aviation company focused on modernizing how consumers access private air travel. Through its Flyte brand, the Company operates a growing fleet of Cirrus Vision Jets and is building a scalable aviation platform designed to connect customers, aircraft, operators, and aviation services. Flyte's simple value proposition: privacy, comfort, reliability, and convenience - at a highly competitive price. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary, Ponderosa Air, LLC, Flyte is focused on delivering what it believes is a faster, safer and more convenient private aviation experience while expanding its technology, customer network, and geographic footprint.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
Latest VJET
- Flyte Aviation Reports Record Third Quarter 2026 Aviation Revenue Increasing 145% Sequentially
- Catheter Precision Partners With Two New German Heart Centers
- Flyte Aviation Launches Flyte Club to Disrupt Jet Cards and Fractional Ownership Programs with Transparent Per-Trip Pricing and Savings Up to 30%
- Flyte Aviation Executes Letter of Intent to Sell Cardiology Assets
- Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population
- Flyte Aviation Expands International Operations to Canada
- Flyte Aviation, One of the Nation’s Largest Vision Jet Operators, Congratulates Cirrus Aircraft on Ten Years of Innovation
- Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device
- Flyte Aviation Establishes New B2B Distribution Channel, Launches Partner Portal
- Flyte Aviation Partners with The Philadelphia 76ers